retatrutide weight loss study results Lilly orforglipron oral GLP-1 phase 3 trial Nearly 30% average weight loss

However, these mechanisms may relate to a combination of effects on weight, blood pressure, glucose and lipid levels, inflammation, and potential effects on other factors promoting atherothrombosis [5]

A review of the pharmacotherapy of obesity: GLP-1 receptor agonists

A small amount may be okay for some people, but more than that can dull arousal and lower blood pressure

This ensures that any changes in your weight or metabolism are managed safely, reducing the risk of adverse interactions with other medications

Over time, the associated risk reduction continued to drop: At 7 years, GLP-1 users had an 87 percent lower risk